Peter G. Butera
Profile
Peter G.
Butera worked as a Vice President and Senior Director in various pharmaceutical companies such as Afferent Pharmaceuticals, Cassava Sciences, Limerick BioPharma, IntraBiotics Pharmaceuticals, and inVentiv Health Clinical.
He also worked as a Project Director at Labcorp Drug Development, Inc. He completed his undergraduate degree from St. Joseph's University.
Former positions of Peter G. Butera
Companies | Position | End |
---|---|---|
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
COVANCE INC. | Corporate Officer/Principal | - |
inVentiv Health Clinical, Inc.
inVentiv Health Clinical, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health Clinical, Inc. provides clinical research and drug development services. It provides its services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The firm offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. The company was founded in 1984 and is headquartered in Princeton, NJ. | Chief Tech/Sci/R&D Officer | - |
Limerick BioPharma, Inc.
Limerick BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities. | Chief Operating Officer | 24/06/2011 |
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Chief Tech/Sci/R&D Officer | - |
Training of Peter G. Butera
St. Joseph's University | Undergraduate Degree |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
CASSAVA SCIENCES, INC. | Health Technology |
Private companies | 5 |
---|---|
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Limerick BioPharma, Inc.
Limerick BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Their intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies. Their lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, their programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, their programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas. They intend to maximize the value of their product candidates and discovery platform through independent development, licensing and other partnership opportunities. | Health Technology |
inVentiv Health Clinical, Inc.
inVentiv Health Clinical, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health Clinical, Inc. provides clinical research and drug development services. It provides its services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The firm offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. The company was founded in 1984 and is headquartered in Princeton, NJ. | Commercial Services |
Labcorp Drug Development, Inc.
Labcorp Drug Development, Inc. Pharmaceuticals: MajorHealth Technology Covance, Inc. operates as a contract research organization and drug development company. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, clinical development, informatics, clinical testing, commercialization, and manufacturing support. The company was founded on November 12, 1996 and is headquartered in Princeton, NJ. | Health Technology |
Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA. | Health Technology |
- Stock Market
- Insiders
- Peter G. Butera